^
    Back
    Association details:
    Biomarker:HER-2 underexpression
    Cancer:Solid Tumor
    Drug:BB-1701 (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2023
    Title:

    A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.

    Published date:
    05/25/2023
    Excerpt:
    BB-1701 was generally well tolerated up to 2.6 mg/kg dose levels and has shown promising antitumor activity in patients with HER2-overexpression solid tumors.
    DOI:
    10.1200/JCO.2023.41.16_suppl.3029
    Trial ID:
    NCT04257110
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    1887 / 26 - Preclinical development of BB-1701, a HER2-tageting eribulin-containing ADC with potent bystander effect and ICD activity

    Published date:
    03/15/2023
    Excerpt:
    Mode of action studies revealed significant bystander cytotoxicity of BB-1701 to HER2-low cells when co-cultured with HER2-high cells….In conclusion, these comprehensive preclinical data have strongly supported BB-1701 as a potent antitumor agent to cancers including HER2-low expressing and/or cancers insensitive to other HER2-targeting ADCs.